CoChat
Sign Up
Cited by 38Endometrial and Cervical Cancer TreatmentsEstrogen and related hormone effectsBreast Cancer Treatment Studies

The role of 5α-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma

Tanaka, Sota, Miki, Yasuhiro, Hashimoto, Chiaki, Takagi, Kiyoshi, Doe, Zhulanqiqige, Li, Bin, Yaegashi, Nobuo, Suzuki, Takashi +1 more·2015·Molecular and Cellular Endocrinology
DOI 10.1016/j.mce.2014.11.022
Open this paper in CoChat — free account

Abstract

Endometrial carcinoma, especially endometrioid endometrial adenocarcinoma, is an estrogen-dependent tumor that is similar to breast cancer. Androgen is closely associated with other steroid hormones, but its correlation with endometrioid endometrial adenocarcinoma remains largely unclear. We previously demonstrated the expression of the androgen receptor, 5α-reductase type 1, and 5α-reductase type 2 in endometrioid endometrial adenocarcinoma tissue, but androgen action and its correlation with prognosis are unknown. In this study, we measured the tissue and serum concentrations of androgen and performed immunohistochemical analyses of androgen-associated factors in 41 patients. In 86 additional patients, we performed the same immunohistochemical analyses to identify correlations associated with prognosis. We found that 5α-reductase type 1 was associated with intratumoral dihydrotestosterone concentrations, and it was an independent prognostic factor in endometrioid endometrial adenocarcinoma. The poor prognosis of patients negative for both androgen receptor and 5α-reductase type 1 suggests that androgens have inhibitory effects on tumor growth.

Integrity signals

Registry

Crossref · 10.1016/j.mce.2014.11.022

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Expression of 5αR1 (in 65% of samples) is positively correlated with histological grade in endometrial cancer.

    “concluding that expression of 5αR1 (65% of samples) was positively correlated with histological grade (but not clinical grade).”

    From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [87]

  • Women immunonegative for both androgen receptor (AR) and 5αR1 have a poorer prognosis.

    “They found that women immunonegative for both AR and 5αR1 had a poorer prognosis [87]”

    From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [87]

  • Expression of 5αR1 is not correlated with clinical grade in endometrial cancer.

    “concluding that expression of 5αR1 (65% of samples) was positively correlated with histological grade (but not clinical grade).”

    From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [87]

  • Endometrial cancer tissues have an 8-fold elevation in dihydrotestosterone (DHT) compared with normal endometrial tissues.

    “it is notable that a study by the same group revealed that EC tissues had an 8-fold elevation in DHT compared with that in normal endometrial tissues [87].”

    From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [87]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Tanaka, S., Miki, Y., Hashimoto, C., Takagi, K., Doe, Z., Li, B., Yaegashi, N., Suzuki, T., & Ito, K.
Affiliations
Tohoku University (JP)
Corresponding author
Miki, Yasuhiro
ORCID
Venue
Molecular and Cellular Endocrinology
Publisher
Elsevier BV
Published
2015-02
Volume
401
Pages
56-64
ISSN
0303-7207 (ISSN-L)
DOI
10.1016/j.mce.2014.11.022
OpenAlex
W2025629716
Cited by
38
References
2
Citations by year
2026: 3 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 7 · 2017: 3 · 2016: 3 · 2015: 1
FWCI
2.48
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Molecular and Cellular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
endometrial cancer, endometrioid endometrial cancer, 5α-reductase type 1, dihydrotestosterone, androgen receptor, 5α-reductase type 2, androgen signaling, prognostic factors, tumor growth inhibition, estrogen-dependent tumors
MeSH terms
Adult, Aged, Aged, 80 and over, Androgens, Female, Humans, Membrane Proteins, Middle Aged, Prognosis, Dihydrotestosterone, Testosterone, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase, Survival Analysis, Endometrial Neoplasms, Carcinoma, Endometrioid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review